Short Interest in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) Increases By 59.4%

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) was the target of a significant growth in short interest in March. As of March 15th, there was short interest totalling 878,500 shares, a growth of 59.4% from the February 28th total of 551,300 shares. Approximately 13.7% of the company’s stock are short sold. Based on an average daily volume of 1,770,000 shares, the days-to-cover ratio is currently 0.5 days.

Analysts Set New Price Targets

TNXP has been the subject of a number of analyst reports. Noble Financial reissued an “outperform” rating and set a $70.00 target price on shares of Tonix Pharmaceuticals in a research report on Thursday, March 20th. StockNews.com started coverage on Tonix Pharmaceuticals in a research report on Monday, February 10th. They set a “sell” rating on the stock.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the company. Commonwealth Equity Services LLC purchased a new position in shares of Tonix Pharmaceuticals in the 4th quarter valued at about $40,000. Two Sigma Investments LP purchased a new position in shares of Tonix Pharmaceuticals during the 4th quarter valued at approximately $66,000. PFG Investments LLC acquired a new stake in Tonix Pharmaceuticals in the 4th quarter valued at $72,000. Northern Trust Corp purchased a new stake in Tonix Pharmaceuticals in the 4th quarter worth $162,000. Finally, Point72 Asset Management L.P. purchased a new position in Tonix Pharmaceuticals during the fourth quarter valued at $526,000. Institutional investors and hedge funds own 82.26% of the company’s stock.

Tonix Pharmaceuticals Stock Performance

NASDAQ TNXP traded up $0.13 on Monday, reaching $20.30. 994,815 shares of the company’s stock traded hands, compared to its average volume of 711,618. The stock has a 50 day moving average price of $18.79 and a 200-day moving average price of $20.20. The firm has a market cap of $37.94 million, a price-to-earnings ratio of 0.00 and a beta of 2.23. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.81 and a current ratio of 3.33. Tonix Pharmaceuticals has a fifty-two week low of $6.76 and a fifty-two week high of $672.00.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its earnings results on Tuesday, March 18th. The company reported ($9.77) EPS for the quarter, missing analysts’ consensus estimates of ($6.23) by ($3.54). The company had revenue of $2.58 million during the quarter, compared to analysts’ expectations of $3.20 million. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. Equities research analysts predict that Tonix Pharmaceuticals will post -1762.5 EPS for the current fiscal year.

Tonix Pharmaceuticals Company Profile

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.